Glucagon: structure, approvals, trials and label safety

Glucagon is a peptide hormone that raises blood sugar, and this guide covers its FDA approvals, key trials and label warnings, as of November 17, 2026.

Complete guide6 min read

Key takeaway

Glucagon has been FDA-approved since 1960. Current labels approve it for severe hypoglycemia in patients with diabetes. Some products are also approved as a diagnostic aid in radiology. In two Phase 3 trials of a newer product, 98.7% of treatments met the glucose recovery goal, versus 100% with an older product. Neither the Gvoke nor the Baqsimi label carries a boxed warning.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“FDA first approved glucagon on November 14, 1960, according to Drugs@FDA.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited2 in this article · 2 across 1 article on Glucagon
Related productsIncretin analogs

Glucagon is a 29-amino-acid peptide hormone that raises blood sugar. FDA first approved it in 1960, and today’s brands are approved to treat severe hypoglycemia in people with diabetes. This guide covers its structure, mechanism, approvals, key trials and label warnings, using sources checked on November 17, 2026.

Quick answer: Glucagon is a natural peptide hormone and a prescription drug. It raises blood glucose by acting on glucagon receptors in the liver, which then release stored glucose. Approved brands include Baqsimi and Gvoke, and FDA approved the first generic glucagon in December 2020.

Vitrapep does not sell glucagon; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is glucagon?

Glucagon is a hormone made by the pancreas (Müller et al., 2017). As a drug, it is a single chain of 29 amino acids. The Baqsimi label states that this chain is identical to human glucagon. Because it is a short chain of amino acids, glucagon is a peptide. Our overview of peptide hormones places it among related signaling molecules.

PubChem lists the molecular formula as C153H225N43O49S and the molecular weight as 3482.7 g/mol (PubChem). FDA first approved glucagon on November 14, 1960, according to Drugs@FDA. That first product came from Lilly and is now listed as discontinued. GlucaGen followed in 1998, and Baqsimi and Gvoke were approved in 2019.

Table 1

Glucagon: key facts

Fact Detail
Structure Single-chain peptide of 29 amino acids, identical to human glucagon
Class Peptide hormone; acts on the glucagon receptor
Molecular formula C153H225N43O49S
Molecular weight 3482.7 g/mol (PubChem)
First FDA approval November 14, 1960 (Lilly; now discontinued)
Approved brands Baqsimi (2019), Gvoke (2019); GlucaGen (1998) now listed as discontinued; generic since 2020

How does glucagon work?

Glucagon acts mainly on the liver. The Gvoke and Baqsimi labels state that it raises blood glucose by activating hepatic glucagon receptors. That signal makes the liver break down stored glycogen and release glucose into the blood. Both labels add that the liver must hold enough glycogen for this effect to occur.

Glucagon also acts outside the liver. The Gvoke label notes that it relaxes smooth muscle in the stomach, duodenum, small bowel and colon. That effect underlies its approved use as a diagnostic aid during radiology exams.

Research has widened the picture. A 2017 review in Physiological Reviews called glucagon’s effects on lipids, body weight and vascular health “under-acknowledged” (Müller et al., 2017). That is review-level evidence, not a label claim.

What is glucagon approved for?

FDA labels list two uses for glucagon products:

  • Severe hypoglycemia. Baqsimi (2019) is indicated “for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes.” Gvoke (2019) is approved for severe hypoglycemia in adult and pediatric patients aged two and older with diabetes.
  • Diagnostic aid. The Gvoke label covers a separate Gvoke product for use “as a diagnostic aid during radiologic examinations.” Its purpose is to “temporarily inhibit movement of the gastrointestinal tract in adult patients.” Drugs@FDA now lists that product as discontinued.

FDA approved the first generic glucagon, from Amphastar, on December 28, 2020. FDA’s first-generics list gives its uses as “the treatment of severe hypoglycemia” and “use as a diagnostic aid” (FDA, 2020).

What did the key trials of glucagon show?

Glucagon has been approved since 1960, so its recent trials test newer products against older ones. All data below come from studies in people.

Gvoke pivotal trials. Two Phase 3, randomized, blinded crossover trials enrolled 161 adults with type 1 diabetes. They were NCT02656069 (80 adults) and NCT03439072 (81 adults). Researchers induced low blood sugar with insulin. Each participant then received Gvoke at one visit and a Lilly glucagon product at another. The primary goal was a set rise in blood glucose within 30 minutes.

The Gvoke label reports that 98.7% of Gvoke treatments met that goal, versus 100% with the comparator. The result met the prespecified noninferiority margin. Mean time to success was 13.8 minutes versus 10 minutes. The trials were published in 2021 (Christiansen et al., 2021).

Gvoke pediatric study. A single-arm, open-label study enrolled 31 children with diabetes. The label reports that all 30 evaluable children reached the target rise in blood glucose.

Baqsimi trial. In NCT03339453, 70 adults with type 1 diabetes were randomized in an open-label crossover design. The registry lists it as Phase 1. Baqsimi was compared with another glucagon product after insulin-induced hypoglycemia. The Baqsimi label reports treatment success in 100% of both groups.

What side effects does the glucagon label list?

Neither the Gvoke nor the Baqsimi label has a boxed warning. In the Gvoke adult trials (154 adults), the label lists nausea (30%), vomiting (16%), local site swelling (7%) and headache (5%). In the Baqsimi adult trials (153 adults), the label lists nausea (26%), headache (18%), vomiting (15%) and upper respiratory tract irritation (12%).

The labels also list warnings. Glucagon is contraindicated in pheochromocytoma, because blood pressure may rise sharply. It is contraindicated in insulinoma, because it may trigger low blood sugar. Other warnings cover serious allergic reactions and lack of effect when liver glycogen is low. The Gvoke label adds a warning on necrolytic migratory erythema.

What is the regulatory status of glucagon, and is it used in research?

Glucagon is a prescription drug. Drugs@FDA lists Baqsimi and most Gvoke products with a “Prescription” marketing status. FDA’s Drug Safety Communications page, current as of November 9, 2026, lists no communication about glucagon products (FDA, 2026). Its entries on GLP-1 drugs concern a different drug class.

WADA’s 2026 Prohibited List does not name glucagon. Our guide to peptides on the 2026 WADA list explains its sections.

Glucagon is also a research subject in its own right. The 2017 review noted that glucagon analogs stable and soluble in water-based solutions have advanced study of the hormone. Dasiglucagon, a glucagon analog approved by FDA in 2021, is covered in our dasiglucagon guide.

Frequently asked questions about glucagon

Is glucagon a peptide?

Yes. It is a single chain of 29 amino acids, identical to human glucagon. See our guide to types of peptides.

When was glucagon first approved?

Drugs@FDA lists the first approval on November 14, 1960, for a Lilly product that is now discontinued.

Is there a generic glucagon?

Yes. FDA approved the first generic, from Amphastar, on December 28, 2020.

Does glucagon have a boxed warning?

No. Neither the Gvoke nor the Baqsimi label carries one. Their warnings cover pheochromocytoma, insulinoma, allergic reactions and low liver glycogen.

How is dasiglucagon different from glucagon?

Dasiglucagon is a separate molecule, a glucagon analog with its own approval in 2021. It acts on the same receptor. Our dasiglucagon guide covers it.

What to know now

  • Structure: 29 amino acids, identical to human glucagon; 3482.7 g/mol.
  • Mechanism: activates liver glucagon receptors, releasing stored glucose.
  • Approval: first approved in 1960; brands include Baqsimi and Gvoke; generic since 2020.
  • Indications: severe hypoglycemia in patients with diabetes; diagnostic aid in radiology on some labels.
  • Trials: newer products met noninferiority against older glucagon in adults with type 1 diabetes.
  • Safety: no boxed warning; nausea, vomiting and headache are the most common reactions.

What we’re watching

Label changes on DailyMed, where the Gvoke label shows a September 2026 revision. Shifts in marketing status, since Drugs@FDA now lists GlucaGen and the diagnostic Gvoke product as discontinued. New generic approvals after the first in 2020. And FDA action on the related analog dasiglucagon for congenital hyperinsulinism, tracked in our dasiglucagon guide.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 16132283, Glucagon; U.S. Food and Drug Administration 2026, Drugs@FDA: NDA 012122, Glucagon (Lilly); U.S. Food and Drug Administration 2026, Drugs@FDA: NDA 020918, GlucaGen (Novo Nordisk); U.S. Food and Drug Administration 2026, Drugs@FDA: NDA 210134, Baqsimi (Amphastar); U.S. Food and Drug Administration 2026, Drugs@FDA: NDA 212097, Gvoke (Xeris); Amphastar Pharmaceuticals 2025, BAQSIMI (glucagon) prescribing information; Xeris Pharmaceuticals 2026, GVOKE (glucagon) prescribing information; Christiansen 2021, BMJ Open Diabetes Research & Care, 9; U.S. Food and Drug Administration 2020, 2020 first generic drug approvals; U.S. Food and Drug Administration 2026, Drug safety communications; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026; Müller 2017, Physiological Reviews, 97. All 12 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16132283, Glucagon. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16132283
  2. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 012122, Glucagon (Lilly). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012122
  3. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 020918, GlucaGen (Novo Nordisk). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020918
  4. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 210134, Baqsimi (Amphastar). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210134
  5. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 212097, Gvoke (Xeris). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212097
  6. Amphastar Pharmaceuticals. (2025). BAQSIMI (glucagon) prescribing information (revised April 2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1f5df9b-872f-44e5-a18f-f0b68e7e9254
  7. Xeris Pharmaceuticals. (2026). GVOKE (glucagon) prescribing information (revised September 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92385737-dbad-98c5-e053-2995a90a2805
  8. Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021). Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: Two randomized crossover non-inferiority studies. BMJ Open Diabetes Research & Care, 9(1), e002137. https://doi.org/10.1136/bmjdrc-2021-002137
  9. U.S. Food and Drug Administration. (2020). 2020 first generic drug approvals. https://www.fda.gov/drugs/first-generic-drug-approvals/2020-first-generic-drug-approvals
  10. U.S. Food and Drug Administration. (2026). Drug safety communications (content current as of November 9, 2026). https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications
  11. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list
  12. Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017). The new biology and pharmacology of glucagon. Physiological Reviews, 97(2), 721–766. https://doi.org/10.1152/physrev.00025.2016